中国生物医药企业对外授权交易的演变趋势与相关因素分析

于潇依; 裴中斐; 孙一诺; 姚逸凡; 许铭

doi:10.6039/j.issn.1001-0408.2026.14.02

您当前的位置：

首页 >

文章列表页 >

中国生物医药企业对外授权交易的演变趋势与相关因素分析

药事管理 | 更新时间：2026-07-28

- 中国生物医药企业对外授权交易的演变趋势与相关因素分析
- Evolution and associated factors of out-licensing deals by Chinese biopharmaceutical companies
- 中国药房 2026年37卷第14期页码：1805-1812
- 作者机构：
  
  北京大学公共卫生学院全球卫生学系，北京　100191
- 作者简介：
  
  博士研究生。研究方向：医药产业经济。E-mail：xyu2025@stu.pku.edu.cn
  研究员，博士生导师，博士。研究方向：全球卫生、中国医药产业国际化。E-mail：xum2022@pku.edu.cn
- 基金信息：
  
  国家社会科学基金项目(23BGL288)
- DOI：10.6039/j.issn.1001-0408.2026.14.02
  中图分类号： R95
- 收稿：2026-03-18，
  
  修回：2026-07-13，
  
  录用：2026-07-14，
  
  网络首发：2026-07-24，
  
  纸质出版：2026-07-30
- 稿件说明：
移动端阅览
于潇依,裴中斐,孙一诺,等.中国生物医药企业对外授权交易的演变趋势与相关因素分析 [J].中国药房,2026,37(14):1805-1812.

YU Xiaoyi,PEI Zhongfei,SUN Yinuo,et al.Evolution and associated factors of out-licensing deals by Chinese biopharmaceutical companies[J].ZHONGGUO YAOFANG,2026,37(14):1805-1812.
于潇依,裴中斐,孙一诺,等.中国生物医药企业对外授权交易的演变趋势与相关因素分析 [J].中国药房,2026,37(14):1805-1812. DOI： 10.6039/j.issn.1001-0408.2026.14.02.

YU Xiaoyi,PEI Zhongfei,SUN Yinuo,et al.Evolution and associated factors of out-licensing deals by Chinese biopharmaceutical companies[J].ZHONGGUO YAOFANG,2026,37(14):1805-1812. DOI： 10.6039/j.issn.1001-0408.2026.14.02.

摘要

目的

系统分析近20年中国生物医药企业（简称“中国药企”）对外授权交易的数量与规模趋势，并定量识别与交易价值相关的因素，为政策制定者和企业管理者提供科学决策依据。

方法

基于PharnexCloud数据库，收集2005年1月1日－2025年12月31日中国药企对外授权交易信息中披露了具体财务条款的已执行交易，采用Stata SE 18.0对其交易价值、产品特征及交易特征进行描述性统计分析；以交易价值的自然对数值为因变量，建立逐步多元回归模型，分析产品特征、交易特征各变量与交易价值的关联。

结果

共纳入210笔中国药企对外授权交易，累计交易价值约2 141.51亿美元，平均每笔交易价值为10.20亿美元。2020年起，交易市场进入快速扩张阶段，2025年年度交易价值达956.87亿美元，创历史新高。多元回归分析显示，药物发现期产品的交易价值显著低于临床前期产品[回归系数（

）＝－1.995，95%置信区间（CI）为－3.256～－0.734，

＜0.05

]

；肿瘤领域产品交易价值显著高于其他领域产品（

＝0.828，95%CI为0.224～1.431，

＜0.05）；全球范围授权（

＝1.690，95%CI为1.107～2.273，

＜0.05）、包含联合开发安排（

＝0.849，95%CI为0.084～1.615，

＜0.05）与更高的交易价值显著相关。

结论

近20年来，中国药企对外授权交易在数量与规模上均实现了显著增长。肿瘤领域产品、全球范围授权、包含联合开发安排与较高的交易价值显著正相关。

Abstract

OBJECTIVE

To systematically analyze the trends in the volume and value of out-licensing deals by Chinese biopharmaceutical companies over the past two decades， and to quantitatively identify factors associated with deal value， thereby providing an evidence base for policymakers and corporate managers.

METHODS

Based on the PharnexCloud database， information on out-licensing deals disclosed by Chinese biopharmaceutical companies between January 1， 2005 and December 31， 2025 was collected， and executed deals with disclosed specific financial terms were included for analysis. Descriptive statistical analyses of deal value， product characteristics and deal characteristics were performed using Stata SE 18.0； with the natural logarithm of deal value as the dependent variable， stepwise multiple regression models were constructed to examine the associations of product and deal characteristics with deal value.

RESULTS

A total of 210 out-licensing deals were included， with a cumulative deal value of approximately 214.151 billion dollars and a mean deal value of 1.020 billion dollars . The trading market expanded rapidly from 2020 onward， with the annual deal value reaching a record 95.687 billion dollars in 2025. Multiple regression analysis showed that the deal value of products at the drug discovery stage was significantly lower than that at the preclinical stage [regression coefficient （

）＝－1.995， 95% confidence interval （CI）：－3.256 to －0.734，

＜0.05

]

； the deal value of oncology products was significantly higher than that of other therapeutic areas （

＝0.828， 95%CI： 0.224 to 1.431，

＜0.05）； global licensing （

＝1.690， 95%CI： 1.107 to 2.273，

＜0.05） and co-development arrangements （

＝0.849， 95%CI： 0.084 to 1.615，

＜0.05） were significantly associated with higher deal value.

CONCLUSIONS

Out-licensing deals by Chinese biopharmaceutical companies have achieved significant growth in both volume and value over the past two decades. Oncology products， global licensing， and co-development arrangements are significantly and positively associated with higher deal value.

关键词

Keywords

references

Li G Q ， Liu Y ， Hu H X ， et al . Evolution of innovative drug R&D in China [J ] . Nat Rev Drug Discov ， 2022 ， 21 （ 8 ）： 553 - 554 .

Su L ， Liu S ， Li G Q ， et al . Trends and characteristics of new drug approvals in China，2011-2021 [J ] . Ther Innov Regul Sci ， 2023 ， 57 （ 2 ）： 343 - 351 .

Tan R R ， Hua H ， Zhou S Y ， et al . Current landscape of innovative drug development and regulatory support in China [J ] . Sig Transduct Target Ther ， 2025 ， 10 （ 1 ）： 220 .

Hu H X ， Xie C C ， Xu H Y ， et al . Drug discovery in China：a snapshot of recent progress [J ] . Acta Pharm Sin B ， 2022 ， 12 （ 11 ）： 4266 - 4269 .

Simon-Kucher . Fueling global pharma pipelines：the rise of China’s innovations [EB/OL ] .（ 2025-02-06 ）[ 2025-12-15 ] . https：//www.simon-kucher.com/en/insights/fueling-global-pharma-pipelines-rise-chinas-innovations https://www.simon-kucher.com/en/insights/fueling-global-pharma-pipelines-rise-chinas-innovations .

Gloria L . Rebirth of China biotech：unlocking value through “license-out” deals and the journey to global lea-dership in innovative drug discovery [EB/OL ] .（ 2025-10-03 ）[ 2025-12-15 ] . https：//www.premia-partners.com/insight/reborn-of-china-biotech-china-s-transformation-into-a-global-leader-in-drug-discovery-and-development-while-unlocking-value-through-license-out-deals https://www.premia-partners.com/insight/reborn-of-china-biotech-china-s-transformation-into-a-global-leader-in-drug-discovery-and-development-while-unlocking-value-through-license-out-deals .

Jiang Y L ， Zhao G ， Jia L L ， et al . Trends of drug licensing in China：from bring-in to go-global [J ] . Pharmacol Res ， 2024 ， 210 ： 107488 .

Maisy M . Out-licensing is in [EB/OL ] .（ 2025-09-10 ）[ 2025-12-15 ] . https：//law.asia/china-pharma-out-licensing-deals/ https://law.asia/china-pharma-out-licensing-deals/ .

Carina X . China innovative pharma going global：the “DeepSeek moment” of China’s innovative drugs [EB/OL ] .（ 2025-07-21 ）[ 2025-12-15 ] . https：//arc-group.com/china-innovative-pharma/ https://arc-group.com/china-innovative-pharma/ .

PharmCube . 1 357 billion USD：China’s pharmaceutical out-licensing deals hit a record high in 2025 [EB/OL ] .（ 2026-01-05 ）[ 2026-07-09 ] . https：//www.pharmcube.com/newsLibrary/detail?id https://www.pharmcube.com/newsLibrary/detail?id ＝1d8cd 4 a 52615 c 85 b 42 d 8456 e 0692 d 253 .

中国新闻网 . 我国上半年创新药对外授权约 1 100亿美元，创历史新高[EB/OL ] .（ 2026-07-13 ）[ 2026-07-13 ] . https：//www.chinanews.com.cn/cj/2026/07-13/10658402.shtml https://www.chinanews.com.cn/cj/2026/07-13/10658402.shtml .

Villiger R ， Bogdan B . Licensing：pros and cons for biotech [J ] . Drug Discov Today ， 2009 ， 14 （ 5/6 ）： 227 - 230 .

Ruckman K ， McCarthy I . Why do some patents get licensed while others do not? [J ] . Ind Corp Change ， 2017 ， 26 （ 4 ）： 667 - 688 .

Gassmann O ， Krech C A ， Bader M A . Out-licensing in pharmaceutical research and development [M ] //Sohuhmacher A，Hinder M，Gassmann O. Value creation in the pharmaceutical industry：the critical path to innovation . Weinheim ： Wiley-VCH（John Wiley & Sons）， 2016 ： 363 .

Zhai S Y ， Wang Q ， Zhu Z ， et al . Impact of market authorization holder（MAH） system on pharmaceutical innovation in China [J ] . J Pharm Policy Pract ， 2025 ， 18 （ 1 ）： 2551794 .

He H ， Zhan Y Z ， Huo B F ， et al . The impact of national centralized drug procurement policy on firm performance：evidence from Chinese pharmaceutical firms [J ] . Transp Res Part E Logist Transp Rev ， 2025 ， 200 （ C ）： 104225 .

Sytch M ， Bubenzer P . Research on strategic alliances in biotechnology：an assessment and review [M ] //Patzelt A，Brenner T. Handbook of bioentrepreneurship . New York ： Springer ， 2008 ： 105 - 131 .

Chen H ， Chen T J . Governance structures in strategic al-liances：transaction cost versus resource-based perspective [J ] . J World Bus ， 2003 ， 38 （ 1 ）： 1 - 14 .

Das T K ， Teng B S . A resource-based theory of strategic alliances [J ] . J Manag ， 2000 ， 26 （ 1 ）： 31 - 61 .

McCutchen W W ， Swamidass P M . Motivations for strategic alliances in the pharmaceutical/biotech industry：some new findings [J ] . J High Technol Manag Res ， 2004 ， 15 （ 2 ）： 197 - 214 .

Teece D J . Profiting from technological innovation：implications for integration，collaboration，licensing and public policy [J ] . Res Policy ， 1986 ， 15 （ 6 ）： 285 - 305 .

Higgins M J ， Rodriguez D . The outsourcing of R&D through acquisitions in the pharmaceutical industry [J ] . J Financ Econ ， 2006 ， 80 （ 2 ）： 351 - 383 .

Cassiman B ， Veugelers R . In search of complementarity in innovation strategy：internal R&D and external knowledge acquisition [J ] . Manag Sci ， 2006 ， 52 （ 1 ）： 68 - 82 .

Arora A ， Ceccagnoli M . Patent protection，complementary assets，and firms’ incentives for technology licensing [J ] . Manag Sci ， 2006 ， 52 （ 2 ）： 293 - 308 .

Nicholson S . Biotech-pharmaceutical alliances as a signal of asset and firm quality [J ] . J Bus ， 2005 ， 78 （ 4 ）： 1433 - 1464 .

Frei P ， Leleux B . Valuation：what you need to know [J ] . Bioentrepreneur ， 2004 ， 22 ： 1049 - 1051 .

Frei P ， Dev K K . Drug dealers：$20 trillion of in-licensing payments [J ] . Drug Discov Today ， 2013 ， 18 （ 21/22 ）： 1027 - 1029 .

Aryal G ， Ciliberto F ， Farmer L E ， et al . Valuing pharmaceutical drug innovations [PP/OL ] . V5. arXiv （ 2026-05-08 ）[ 2025-12-16 ] . https：//doi.org/10.48550/arXiv.2212.07384 https://doi.org/10.48550/arXiv.2212.07384 .

Dealmakers B . Billion-dollar deals bolster oncology research [J/OL ] . Biopharma Deal ， 2024 . https：//doi.org/10. 1038/d43747-024-00092-w https://doi.org/10.1038/d43747-024-00092-w .

Senior M . Oncology dealmakers seek multi-indication therapies [J/OL ] . Biopharma Deal ， 2025 . https：//doi.org/10.1038/d43747-025-00006-4 https://doi.org/10.1038/d43747-025-00006-4 .

Michaeli D T ， Yagmur H B ， Achmadeev T ， et al . Value drivers of development stage biopharma companies [J ] . Eur J Health Econ ， 2022 ， 23 （ 8 ）： 1287 - 1296 .

Hermosilla M ， Wu Y F . Market size and innovation：the intermediary role of technology licensing [J ] . Res Policy ， 2018 ， 47 （ 5 ）： 980 - 991 .

Chen X Y ， Chu H L ， Zhang X F ， et al . Quality of drug clinical trials in China：a mixed methods research [J ] . J Evid Based Med ， 2025 ， 18 （ 4 ）： e70085 .

Ezekiel J E . The solution to drug prices [EB/OL ] .（ 2015-09-09 ）[ 2025-12-16 ] . https：//www.nytimes.com/2015/09/09/opinion/the-solution-to-drug-prices.html https://www.nytimes.com/2015/09/09/opinion/the-solution-to-drug-prices.html .

Gores M ， Harries W ， Capuzzi F . Inflection point：how clinical trial results impact biopharma valuations [EB/OL ] . [ 2025-12-16 ] . https：//www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/how-clinical-trial-results-impact-bioph-arma-valuations.pdf https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/how-clinical-trial-results-impact-bioph-arma-valuations.pdf .

Mills M ， Michaeli D ， Miracolo A ， et al . HTA4 clinical development and HTA approval of MULTI-indication oncol-ogy products：evidence from Germany，France，England，Scotland，the US，Canada，and Australia [J ] . Value Heal ， 2020 ， 23 ： S403 .

Moser J ， Verdin P . Trial watch：burgeoning oncology pipeline raises questions about sustainability [J ] . Nat Rev Drug Discov ， 2018 ， 17 （ 10 ）： 698 - 699 .

Levine J A ， Stemitsiotis C . De-risking rare disease acquisitions：a win-win-win for patients，biotech and investors [J ] . Nat Rev Drug Discov ， 2024 ， 23 （ 1 ）： 10 - 11 .

Marshall A . The year of the bispecific in oncology and beyond [J/OL ] . Biopharma Deal ， 2025 . http：//doi.org/10.1038/d43747-025-00111-4 http://doi.org/10.1038/d43747-025-00111-4 .

Rooswinkel R W ， Berbers D S ， Claassen E H ， et al . Venturing across the Atlantic [J ] . Nat Biotechnol ， 2016 ， 34 （ 11 ）： 1095 - 1098 .

Skerritt J H ， Mayer M ， Francer J . Strengthening the use of international collaborative regulatory assessments and regulatory alignment-implications for global convergence [J ] . Ther Innov Regul Sci ， 2025 ， 59 （ 5 ）： 993 - 1003 .

BAYER M . House panel calls for banning China data from FDA drug trial applications [EB/OL ] . [ 2026-04-30 ] . https：//endpoints.news/house-panel-calls-to-ban-china-trial-data-from-fda-drug-trial-applications/ https://endpoints.news/house-panel-calls-to-ban-china-trial-data-from-fda-drug-trial-applications/ .

Aulakh P S ， Jiang M S ， Li S L . Licensee technological potential and exclusive rights in international licensing：a multilevel model [J ] . J Int Bus Stud ， 2013 ， 44 （ 7 ）： 699 - 718 .

Shah P ， Vaughan G ， Ledley F D . Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms [J ] . PLoS One ， 2023 ， 18 （ 3 ）： e0283887 .

L.E.K. Consulting . Trends in pharma asset licensing and deal terms：a survey of key decision-makers [EB/OL ] .（ 2021-03-19 ）[ 2026-04-20 ] . https：//www.lek.com/insights/ei/2020-pharma-asset-licensing https://www.lek.com/insights/ei/2020-pharma-asset-licensing .

Batun S ， Begen M A ， Zaric G S . Optimal co-development contracts for companion diagnostics [J ] . Eur J Oper Res ， 2025 ， 323 （ 1 ）： 241 - 252 .

Liao T ， He M D . Understanding the NewCo model：a trending approach of Chinese pharmaceutical companies [EB/OL ] . [ 2025-12-26 ] . https：//www.morganlewis.com/pubs/2024/10/understanding-the-newco-model-a-trending-approach-of-chinese-pharmaceutical-companies https://www.morganlewis.com/pubs/2024/10/understanding-the-newco-model-a-trending-approach-of-chinese-pharmaceutical-companies .

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

镰形棘豆炮制品改善大鼠肾纤维化的作用及机制研究

ω-3多不饱和脂肪酸联合氯米芬对多囊卵巢综合征患者疗效、妊娠和安全性的影响

治疗重症肌无力的抗体类药物临床应用与药学管理循证专家共识

基于“五级定位”理念的药品货位智能定位软件设计及管理方案实践研究

基于德尔菲法构建医疗机构制剂成本项目库